PIK3CA mutation

2/6 #TumorBoardTuesday ThursCase🎀 Take🏠msgs: #metastatic HR+ #breastcancer ✅ NGS is 🗝️ in ER+ mBC on CDK4/6i ✅ ESR1 mut➡️Elacestrant ✅ No ESR1 mutation, but PIK3CA mut, consider 🎯tx, beware side effects 📚Here’s @ilanaschlam @drsarahsam’s thread https://t.co/DcA8w8ofI9 (@JohnEbbenMDPhD)

#TumorBoardTuesday #BCSM There are several promising PIK3CA mutant specific inhibitors in clinical trials which is always recommended. They are supposed to have favorable side effects. Fingers crossed! (@drsarahsam)

#PIK3CA is oft mutated in #breastcancer, #CRC and #endometrialcancer - but not oft discussed at #ASCO23. Surely it deserves its name in lights? (@drmcopeman)

APBCS - Molecular tumor board for breast cancer! Has breast cancer ever been more interesting/complicated ! Multiple PIK3CA mutations and BRCA2! @Shaheenah1 @hoperugo @jhaveri_komal @VKaklamani @ (@RebeccaDSing)

WATCH: @jhaveri_komal, of @MSKCancerCenter, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer. #bcsm https://t.co/1AFlJvEwa5 (@OncLive)

Thank you to @BCAllianceCT for a Young Investigator Grant for our research on PIK3CA mutations in breast cancer. We are grateful for your investment in our lab! https://t.co/tkGcNxFGPt (@NeilVasan)

In an evaluation of patients with endometrioid ovarian carcinoma, ARID1A mutations occurred in 39% of patient samples, and PIK3CA mutations had an incidence rate of 38%. @DNasioudis @PennMedicine @SGO_org #gyncsm #SGOMtg https://t.co/ploujsZcIc (@OncLive)

Just in time for #AACR23 👉The emerging role of PI3K inhibitors for solid tumour treatment and beyond has been published in @BrJCancer @curijoey @PTarantinoMD @OncoAlert 👉The advent of allosteric mutant and isoform selective PIK3CA inhibitors, some of which are currently… https://t.co/MKDA91tYLa (@VivekSubbiah)

In this 1st-in-human phase 1b study, the pan-AKT inhibitor vevorisertib as monotherapy or in combo w/ paclitaxel or fulvestrant had a generally manageable safety profile in pats w/ PIK3CA/AKT/PTEN-mutated advanced solid tumors. 🔗 https://t.co/OrAWPs2Nnf CC: @VivekSubbiah (@JournalCancer)

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors https://t.co/Km5su3JsLP (@ErikaHamilton9)

The #ALPHABET study in patients with HER2+ metastatic #breastcancer and PIK3CA mutation is ongoing at the IEO; for information and to participate, contact divisione.svilupponuovifarmaci@ieo.it https://t.co/SABsdYTDRM @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)

One more attempt to justify the poorer outcomes of young women with breast cancer. Genomic features of HRD, PIK3CA mutations with CN-amplifications, and CN-amplifications are enriched in very young women https://t.co/c87tlNepxo (@antgiorda)

We previously showed that breast tumors with multi-PIK3CA mutations correlate with increased PI3Ki sensitivity. Our pan-tumor study provides new insights into the genetic heterogeneity and tissue specificities of multi-PIK3CA mutations, to guide PI3Ki strategies in the clinic. (@NeilVasan)

🎥 @hoperugo of @UCSFCancer talks on BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer Watch: 👉https://t.co/Y1SYVz4giP👈 @SABCSSanAntonio #SABCS22 #BCSM #BreastCancer (@VJOncology)

Dr Robert Wesolowski, Associate Professor, presented data from the Phase 1 Gedatolisib + Palbociclib + Endocrine Tx in #mBC with PIK3CA mutation at #SABCS22 #bcsm @OSUWexMed @OSUCCC_James He leads our Phase 1 efforts (@DrGattiMays)

4. And of course, we have the poll/consensus (not) by @PTarantinoMD on 2L "de-novo HR+ MBC... ESR1-mutant disease (no PIK3CA mut)" post #SABCS22. https://t.co/Jjwpif8ZoS (@OncBrothers)

In CALGB 40601 PIK3CA mutations were predictive and prognostic, driven by luminal subtype esp LumB - work by Paola Zagami. In same poster discussion, intriguing early data of adding PI3Ki MEN1611 to anti HER2 Rx by Martine Piccart. @UNCBreastSPORE #SABCS22 @ALLIANCE_org (@DrLisaCarey)

Today at #SABCS22, @hoperugo presents long term disease control data from a Phase II trial after CDK4/6i treatment in patients with the PIK3CA driver mutation in HR+/HER2- Advanced #BreastCancer. Abstract PD13-06 https://t.co/VU0I0z6Tmt (@NovartisOncMed)

#capivasertib plus #fulvestrant another second line option endocrine therapy patients breast cancer #CAPItello trial Nick Turner. Good for pts that scene is becoming crowded w more options: Alpelisib if PIK3CA mutated tumors, oral SERDs, T-Dxd if HER2 low, … #SABCS22 @OncoAlert (@NagiSaghir)

It was an honor to collaborate with @hoperugo on a study about the extended spectrum of PIK3CA mutations in #breastcancer, and the outcomes of patients with such mutations on alpelisib (Piqray) + fulvestrant. Paper published online first in @CCR_AACR: https://t.co/G7ZDxMhVsz (@HTukachinsky)

30-40% of all breast cancer have PIK3CA GOF/activating mutations. Only Phase III+ data available available for benefit of targeting is in HR+ currently, but ongoingn trials in #TNBC (@Dr_RShatsky)

Biology and targetability of the extended spectrum of PIK3CA mutations (PIK3CAm) detected in breast carcinoma https://t.co/zbvucnb0gy Very nice paper, worthy of a "slow reading"😉 (@FilippoMontemu1)

An interesting study for #HER2-positive breast cancers with activating mutations in #PIK3CA is less likely to benefit from #neoadjuvant treatment with #pirotinib combined with #trastuzumab. @BCTrials @BreastCaupdates @BCancerAcademy https://t.co/B5hQAB8fjy (@Dr_Ivanoncologo)

Lobular #BreastCancer is molecularly different from IDC. #ctDNA mutations in CDH1, ERBB2, PTEN were associated with ILC. Similarly, CDH1 was co-mutated with PIK3CA, ERBB2 and ET resistance alterations in a cohort of ~7000 #MBC patients #bcsm #LiquidBiopsy https://t.co/Tx2fmuhug3 (@LGerratana)

Lobular #BreastCancer was associated with #ctDNA mutations in CDH1, ERBB2 and PTEN. Similarly, in an independent cohort of ~7000 #MBC patients, CDH1 was co-mutated with targetable (PIK3CA, ERBB2) and endocrine resistance alterations. #bcsm #LiquidBiopsy https://t.co/Tx2fmuhug3 (@LGerratana)

✳️Some important points: biomarker before starting therapy ! RAS/RAF mutations and perhaps also PIK3CA which may render resistance to HER2 therapy ❗️ ✳️Similar to antiEGFR therapy, patients with left sided colon cancer seems to benefit more from HER2 therapy over right sided❗️ (@IbrahimSahinMD1)

2/ #TumorBoardTuesday Thurs Case🎀 Take🏠messages : PIK3CA mutations in ER+ #mBC ✅PIK3CA mut are common- 20-30% of all #BreastCancer & 40%+ of ER+ #mBC ✅PIK3CAm are present in founder clones! 📚We captured as much of the discussion as we could: Pt 1 https://t.co/GOP7lEwc3y (@JohnEbbenMDPhD)

#PostTest Q2️⃣ #CME #TumorBoardTuesday 👉🏽Free CME🔗: https://t.co/7sDmd4BRzd 👨🏽‍🦳Male who has stage 4 (M1) #BreastCancer with tumor HR+/HER2- & PIK3CA mutation, previously tried aromatase inhibitor + a GnRH analog + ribociclib. 🧐What therapy would YOU recommend? (@JasmineSukumar)

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽CME Eval 🔗: https://t.co/x2AxRWljls 🤔 @maryam_lustberg @JasmineSukumar taught us PIK3CA #BreastCancer treatment, test your 🧠 with 2❓ 🧐 What would be your next step if a PIK3CA mutation wasn’t detected in plasma? (@JasmineSukumar)

#TumorBoardTuesday Got it! 5⃣Order of what to add to endocrine therapy for HR+ breast cancer: a) CDK4/6 inhibitors b) PIK3CA inhibitors (if PIK3CA mutated) (@MPishvaian)

6/17 #TumorBoardTuesday #BCSM 👩🏽‍🏫Mini tweetorial 4 👩🏻‍🏫 ✨SOLAR-1✨ 🌞PIK3CA mutation results 📍PFS ⬆️ 5.3 mo (HR 0.65, p<0.001) 📍OS ⬆️ 7.9 mo (HR 0.86, p=0.15) ✅benefit across subgroups ❌PIK3CA non-mutated no benefit 📚https://t.co/IWi82eJmUJ (@JasmineSukumar)

10/17 #TumorBoardTuesday #BreastCancer 📆When is the ideal time to test for PIK3CA mutation❓ 🧪Test in HR+ MBC at diagnosis or after CDK4/6i progression 🔸BYLieve cohort A: 👉🏽 alpelisib benefit after CDK4/6i+AI (median PFS 7.3 mo) 📚@hoperugo https://t.co/AyZcHmCDGz (@JasmineSukumar)

8/17 #TumorBoardTuesday #BreastCancer 🕵🏻‍♀️There’s several platforms for detecting PIK3CA activating mutation in real world practice 📊Which 🧬 genomic profiling test do YOU most commonly use in practice? (@JasmineSukumar)

#TumorBoardTuesday I am going to start counting the NEW facts I learn tonight: 1⃣PIK3CA mutations present in 20-30% of #breastcancer and 40% of HR+ breast cancers 2⃣PIK3CA mutations are truncal‼️ (@MPishvaian)

NICE approves two treatment options for advanced breast cancer https://t.co/MraoHvwr6i Alpelisib first targeted treatment for patients with PIK3CA mutation found in 30-40% of oestrogen receptor positive HER2 negative breast cancers @DrIanWeissman @SusanChubb1 @SirGeoffPalmer (@Nigelj08223326)

PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer | JCO Precision Oncology https://t.co/UkQvslT2QV (@weldeiry)

By selecting out for RAS mutated PIK3CA/PTEN WT (MEKi ss pre-clinically), we still did not uncover clinical activity for MEK inhibition in MCRC when combined with trifluridine. A disappointing journey for MEKi in mCRC- for providers and for pts! https://t.co/nMhhKqWcWW (@mgfakih)

We do not observe any significant effect/ enrichment of Akt/ PIK3CA mutation in prostate cancer. Interestingly in breast cancer activating mutations of PIK3CA are enriched in HR+HER2- disease, whereas PIK3R1 mutations are enriched in TNBC. (@Goutam_Chak)

Join .@Cecchini_OncMD in Hall A #ASCO22 presenting a poster on “Molecular Characteristics of Advanced Colorectal Cancer and Multi-Hit PIK3CA Mutations” from 8:00am – 11:00amCST. #colorectalcancer @ASCO @YaleGICancers @SmilowCancer https://t.co/RvgMU6GhE7 (@YaleCancer)

SOLAR-1 alpelisib update takeaway: 📍Targeting activating PIK3CA mutations WORKS. 📍We need to test & treat! #ASCO22 #bcsm (@DrSGraff)

Will you go to fulvestant + CDK4/6i in a PIK3CA mutated tumor next or 2nd line AI + CDK4/6i and save fulvestrant for alpelisib for next (3rd) line or just skip the second line CDK 4/6i all together??? 🤔 #bcsm #ASCO22 (@DrLaurenNye)

Agree with importance of accurately defining AKT1 and PIK3CA status in mCRPC and yes seems like there is a spectrum of oncogenic addiction. e.g. MMRd/MSI-H tumors often accrue AKT1/PIK3CA mutations, but they are likely to have plenty of redundancy. https://t.co/czhdQVKRdy (@ResearchWyatt)